WallStreetZenWallStreetZen

NASDAQ: BCTX
Briacell Therapeutics Corp Earnings & Revenue

Buy BCTX

BCTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$11.4M
Current Profit Margin
0%

BCTX Return on Equity

Current Company
-27.8%
Current Industry
6.9%
Current Market
38.4%
BCTX's Return on Equity (-27.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BCTX announces earnings.

BCTX Return on Assets

Current Company
-27.4%
Current Industry
5.1%
BCTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BCTX Return on Capital Employed

Current Company
-31.33%
Current Industry
-16.5%

BCTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BCTX$0.00-$11.27M-$11.20MN/AN/A
PIRS$27.19M-$38.91M-$41.51M+32.30%N/A
LPTX$750.00k-$49.28M-$49.33M0.00%N/A
FIXX$4.08M$5.81M-$1.18M+12.78%N/A
GNTA$0.00-$5.99M-$6.01MN/AN/A

Briacell Therapeutics Earnings & Revenue FAQ

What were BCTX's earnings last quarter?

Briacell Therapeutics (NASDAQ: BCTX) reported Q1 2022 earnings per share (EPS) of -$0.25, up 149.61% year over year. Total Briacell Therapeutics earnings for the quarter were -$3.84 million. In the same quarter last year, Briacell Therapeutics's earnings per share (EPS) was $0.51.

If you're new to stock investing, here's how to buy Briacell Therapeutics stock.

What was BCTX's earnings growth in the past year?

As of Q3 2022, Briacell Therapeutics's earnings has grown year over year. Briacell Therapeutics's earnings in the past year totalled -$11.20 million.

What was BCTX's revenue last quarter?

Briacell Therapeutics (NASDAQ: BCTX) reported Q1 2022 revenue of $0.00 up N/A year over year. In the same quarter last year, Briacell Therapeutics's revenue was $0.00.

What was BCTX's revenue growth in the past year?

As of Q3 2022, Briacell Therapeutics's revenue has grown null year over year. Briacell Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.